person · Reporting owner

DOYLE WILLIAM F

Disclosed activity across 5 companies

Tapewire entity: 43193
SEC CIK: 0001194459

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Elanco Animal Health IncELAN · Entity 3457	Director	November 29, 2024	December 03, 2024
Minerva Neurosciences, Inc.NERV · Entity 6245	Director	June 10, 2022	June 28, 2022
NovoCure LtdNVCR · Entity 4494	Director · Executive Chairman	March 03, 2026	March 05, 2026
OptiNose, Inc.OPTN · Entity 79464	Director	June 10, 2020	June 12, 2020
PROKIDNEY CORP.PROK · Entity 5181	Director	May 28, 2026	May 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Elanco Animal Health Inc

Report date November 29, 2024 · Filed December 03, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	94,499	Reported balance After 2024-11-29 transaction · row 1 1 source row Row 1 · 2024-11-29 · Grant · Acquired 18,169 · Balance 94,499 F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

Minerva Neurosciences, Inc.

Report date June 10, 2022 · Filed June 28, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.32 · Expires 2032-06-09	Direct	2,500	Reported balance After 2022-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-10 · Grant · Acquired 2,500 · Balance 2,500 F1: This option is granted to non-employee directors in accordance with the Issuer's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 2,500 shares of common stock per year. F2: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F3: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 10, 2022 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option is granted to non-employee directors in accordance with the Issuer's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 2,500 shares of common stock per year.

F2: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split.

F3: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 10, 2022 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.

NovoCure Ltd

Report date March 03, 2026 · Filed March 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	200,000	Reported balance After 2026-03-03 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-03-03 · Grant · Acquired 200,000 · Balance 200,000 F1: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.
Ordinary SharesSEC Table I · non-derivative	Direct	400,284	Reported balance After 2026-03-03 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2026-03-03 · Grant · Acquired 200,284 · Balance 400,284 F2: Represents vesting of performance-based restricted stock units.
Ordinary SharesSEC Table I · non-derivative	Direct	349,727	Reported balance After 2026-03-03 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2026-03-03 · Sale · Disposed 50,557 · Balance 349,727 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4: This transaction was executed in multiple trades at prices ranging from $12.299 USD to $13.277 USD; the price reported above reflects the weighted average sale price.
Ordinary SharesSEC Table I · non-derivative	Direct	328,397	Reported balance After 2026-03-03 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2026-03-03 · Sale · Disposed 21,330 · Balance 328,397 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5: This transaction was executed in multiple trades at prices ranging from $13.35 USD to $13.52 USD; the price reported above reflects the weighted average sale price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-03-03	Direct	258,445	Reported balance After 2026-03-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-03-03 · Grant · Acquired 258,445 · Balance 258,445 F6: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-03-03	Direct	288,517	Reported balance After 2026-03-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-03-03 · Grant · Acquired 30,072 · Balance 288,517 F6: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.

F2: Represents vesting of performance-based restricted stock units.

F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4: This transaction was executed in multiple trades at prices ranging from $12.299 USD to $13.277 USD; the price reported above reflects the weighted average sale price.

F5: This transaction was executed in multiple trades at prices ranging from $13.35 USD to $13.52 USD; the price reported above reflects the weighted average sale price.

F6: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.

OptiNose, Inc.

Report date June 10, 2020 · Filed June 12, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.65 · Expires 2030-06-09	Direct	14,439	Reported balance After 2020-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-06-10 · Grant · Acquired 14,439 · Balance 14,439 F1: The option vests and becomes exercisable on the earlier of (i) June 10, 2021 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2021 annual meeting of stockholders, subject to continued service with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and becomes exercisable on the earlier of (i) June 10, 2021 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2021 annual meeting of stockholders, subject to continued service with the Issuer.

PROKIDNEY CORP.

Report date May 28, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.81 · Expires 2036-05-28	Direct	135,000	Reported balance After 2026-05-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-28 · Grant · Acquired 135,000 · Balance 135,000 F1: These options were granted under the Issuer's non-employee director compensation policy. F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

Filing footnotes · ownership attribution and instrument terms

F1: These options were granted under the Issuer's non-employee director compensation policy.

F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 02, 2017 Filed May 4, 2017 20:06 UTC	NovoCure Ltd NVCR · Entity 4494	GrantRestricted Stock Unit · Derivative	881,519	$0.00	$0.00	Disclosure SEC source: 0000899243-17-011809 · doc4.xml · derivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881,519 Underlying: Ordinary shares · 881,519 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share. F4 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of May 2, 2018, May 2, 2019, and May 2, 2020, subject to Mr. Doyle's continued employment through such dates. F4 · derivative.expiration_date: One-third of these restricted stock units are scheduled to vest on each of May 2, 2018, May 2, 2019, and May 2, 2020, subject to Mr. Doyle's continued employment through such dates. Read SEC document
May 02, 2017 Filed May 4, 2017 20:06 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOptions to Buy Ordinary Shares · Derivative	881,519	$0.00 Strike: $11.85	$0.00	Disclosure SEC source: 0000899243-17-011809 · doc4.xml · derivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881,519 Underlying: Ordinary shares · 881,519 shares Expires 2027-05-02 F2 · derivative.exercise_date: Options to buy 881,519 ordinary shares will fully vest and become exercisable on May 2, 2022 if (i) the closing price of the Company's ordinary shares is at least $22.50 for a period of at least twenty (20) consecutive trading days at any time between May 2, 2017 and May 2, 2022 and (ii) Mr. Doyle has been continuously employed by the Company through May 2, 2022. Read SEC document
May 02, 2017 Filed May 4, 2017 20:06 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOptions to Buy Ordinary Shares · Derivative	881,519	$0.00 Strike: $11.85	$0.00	Disclosure SEC source: 0000899243-17-011809 · doc4.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881,519 Underlying: Ordinary shares · 881,519 shares Expires 2027-05-02 F1 · derivative.exercise_date: Options to buy 881,519 ordinary shares will fully vest and become exercisable on May 2, 2020 if (i) the closing price of the Company's ordinary shares is at least $14.81 for a period of at least twenty (20) consecutive trading days at any time between May 2, 2017 and May 2, 2020 and (ii) Mr. Doyle has been continuously employed by the Company through May 2, 2020. Read SEC document
March 08, 2017 Filed Mar 9, 2017 22:08 UTC	NovoCure Ltd NVCR · Entity 4494	OtherOrdinary Shares	19,732,767	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-007012 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund II, L.P. Disclosed balance after: 43,000 F1 · kind: On March 8, 2017, WFD Ventures Fund II, L.P. distributed, on a pro-rata basis and without consideration, to its economic partners 19,732,767 of the Issuer's shares, including 625,954 of such shares to WFD-GP II, LLC. F1 · price: On March 8, 2017, WFD Ventures Fund II, L.P. distributed, on a pro-rata basis and without consideration, to its economic partners 19,732,767 of the Issuer's shares, including 625,954 of such shares to WFD-GP II, LLC. F2 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document
February 28, 2017 Filed Mar 3, 2017 00:21 UTC	NovoCure Ltd NVCR · Entity 4494	Exercise / conversionWarrants · Derivative	525,618	$0.00 Strike: $3.59	$0.00	Disclosure SEC source: 0000899243-17-006165 · doc4.xml · derivative · entry 7 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund II, L.P. Disclosed balance after: 0 Underlying: Ordinary Shares · 525,618 shares Expires 2018-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Currently exercisable as of the date hereof. F1 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document
February 28, 2017 Filed Mar 3, 2017 00:21 UTC	NovoCure Ltd NVCR · Entity 4494	Exercise / conversionWarrants · Derivative	686,836	$0.00 Strike: $3.59	$0.00	Disclosure SEC source: 0000899243-17-006165 · doc4.xml · derivative · entry 6 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund II, L.P. Disclosed balance after: 0 Underlying: Ordinary Shares · 686,836 shares Expires 2017-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Currently exercisable as of the date hereof. F1 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document
February 28, 2017 Filed Mar 3, 2017 00:21 UTC	NovoCure Ltd NVCR · Entity 4494	Tax withholdingOrdinary Shares	248,285	$7.60	$1,886,966.00	Disclosure SEC source: 0000899243-17-006165 · doc4.xml · nonDerivative · entry 4 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund II, L.P. Disclosed balance after: 19,775,767 F3 · kind: Reflects 248,285 ordinary shares withheld by the issuer at the market price of $7.60 per share less an exercise price of $3.59 per share in connection with the cashless exercise of 277,333 warrants to purchase ordinary shares owned by WFD Ventures Fund II, L.P. F1 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document
February 28, 2017 Filed Mar 3, 2017 00:21 UTC	NovoCure Ltd NVCR · Entity 4494	Exercise / conversionOrdinary Shares	525,618	$3.59	$1,886,968.62	Disclosure SEC source: 0000899243-17-006165 · doc4.xml · nonDerivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund II, L.P. Disclosed balance after: 20,024,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document
February 28, 2017 Filed Mar 3, 2017 00:21 UTC	NovoCure Ltd NVCR · Entity 4494	Tax withholdingOrdinary Shares	324,440	$7.60	$2,465,744.00	Disclosure SEC source: 0000899243-17-006165 · doc4.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund II, L.P. Disclosed balance after: 19,498,434 F2 · kind: Reflects 324,440 ordinary shares withheld by the issuer at the market price of $7.60 per share less an exercise price of $3.59 per share in connection with the cashless exercise of 362,396 warrants to purchase ordinary shares owned by WFD Ventures Fund II, L.P. F1 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document
February 28, 2017 Filed Mar 3, 2017 00:21 UTC	NovoCure Ltd NVCR · Entity 4494	Exercise / conversionOrdinary Shares	686,836	$3.59	$2,465,741.24	Disclosure SEC source: 0000899243-17-006165 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund II, L.P. Disclosed balance after: 19,822,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: The Amendment filed on Form 4/A on February 21, 2017 incorrectly reflected the total number of ordinary shares beneficially owned by WFD Ventures Fund II, L.P. WFD Ventures Fund II, L.P. beneficially owned 19,136,038 ordinary shares following the transactions reported by the aforementioned Form 4/A. F1 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document
January 03, 2017 Filed Jan 4, 2017 21:01 UTC	NovoCure Ltd NVCR · Entity 4494	OtherOrdinary Shares	2,242,664	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-000224 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund A, LLC Disclosed balance after: 0 F1 · kind: On January 3, 2017, WFD Ventures Fund A, LLC distributed to its sole economic member all of the Issuer shares that it held in connection with its liquidation. Neither Mr. Doyle nor WFD Ventures Fund II, L.P. had any pecuniary interest in the distributed shares. F1 · price: On January 3, 2017, WFD Ventures Fund A, LLC distributed to its sole economic member all of the Issuer shares that it held in connection with its liquidation. Neither Mr. Doyle nor WFD Ventures Fund II, L.P. had any pecuniary interest in the distributed shares. F2 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, which is the managing member of WFD Ventures Fund A, LLC. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.